Abstract. The majority of human melanoma cell lines secretes vascular endothelial growth factor-A (VEGF-A) and expresses its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP-1), a co-receptor for VEGF-A that amplifies the signalling through VEGFR-2. Since it is known that the VEGF-A/VEGFR-2 autocrine loop promotes melanoma cell invasiveness, the aim of the present study was to investigate the involvement of NPR-1 in melanoma progression. Syngeneic human melanoma cell lines expressing either VEGFR-2 or NRP-1, both or none of them, were analyzed for their in vitro ability to migrate, invade the extracellular matrix (ECM) and secrete active metalloproteinase-2 (MMP-2). The results indicate that NRP-1 cooperates with VEGFR-2 in melanoma cell migration induced by VEGF-A. Moreover, NRP-1 expression is sufficient to promote MMP-2 secretion and melanoma cell invasiveness, as demonstrated by the ability of cells expressing solely NRP-1 to spontaneously invade the ECM. This ability is specifically downregulated by anti-NRP-1 antibodies or by interfering with NRP-1 expression using an shRNA construct. Investigation of the signal transduction pathways triggered by NRP-1 in melanoma cells, indicated that NRP-1-dependent promotion of cell invasiveness involves Akt activation through its phosphorylation on T308. Overall, the results demonstrate that NRP-1 is involved in melanoma progression through VEGFR-2-dependent and -independent mechanisms and suggest NRP-1 as a target for the treatment of the metastatic disease.
Introduction
Cutaneous malignant melanoma is the most aggressive form of skin cancer, being endowed with high invasiveness and metastatic potential (1, 2) . Melanoma progression is greatly favoured by angiogenesis and appears to be associated with an increase of vascular endothelial growth factor-A (VEGF-A) expression by the tumour cells (3) .
VEGF-A interacts with two high affinity transmembrane tyrosine kinase receptors that are selectively, though not exclusively, expressed by the vascular endothelium (4), namely VEGFR-1 (also known as Flt-1) and VEGFR-2 (or KDR). VEGF-A also binds to neuropilin-1 (NRP-1), a surface polypeptide that, acting as co-receptor, amplifies the signal transmitted by VEGF-A through the VEGFR-2 (5-8).
NRP-1 is a 130-kDa single-spanning transmembrane glyc oprotein with a large extracellular domain and a short cytoplasmic tail (44 amino acids), which lacks a defined signalling activity (5, 6) . It was initially identified as an adhesion molecule in the nervous system. Subsequently, NRP-1 was found to act in neurons as a receptor for class 3 semaphorins (a family of secreted polypeptides with key roles in axonal guidance) and in vascular endothelial cells as a receptor for various members of the VEGF family.
NRP-1 expression has been detected by immunostaining in tumour specimens obtained from patients with prostate, lung, pancreatic or colon carcinoma, but not in the matched normal epithelial tissues. Moreover, NRP-1 is expressed in several other tumours, including melanoma, astrocytoma, malignant glioma and neuroblastoma (reviewed in ref. 5) , suggesting a critical role for this receptor in tumour progression (9) . Actually, overexpression of NRP-1 has been demonstrated to be positively associated with the aggressiveness and the invasive behaviour of tumour cells (10, 11) .
The majority of human melanoma cell lines, derived from primary or metastatic lesions, secretes VEGF-A and expresses VEGFR-1, VEGFR-2 and neuropilins (12) . Moreover, we previously demonstrated that an autocrine loop sustained by the interaction of VEGF-A with VEGFR-2 promotes melanoma cell ability to migrate and invade the extracellular matrix (ECM) in vitro (13) . Therefore, the aim of the present study was, to investigate whether NRP-1 participates as co-receptor in the VEGF-A/VEGFR-2-dependent autocrine loop, contributing to melanoma cell invasiveness. The results indicate that NRP-1 cooperates with VEGFR-2 in promoting melanoma cell migration and ECM invasion. Moreover, NRP-1 expression confers melanoma cells an elevated invasiveness, even in the absence of VEGFR-2 expression.
Materials and methods
Reagents. Cell culture media and reagents were purchased from Lonza (Basel, Switzerland); fetal bovine serum (FBS) was from Euroclone (Pero, Italy), heparin, antibiotics and gelatin from Sigma-Aldrich (St. Louis, MO) and fatty acidfree bovine serum albumin (BSA) from Roche (Mannheim, Germany). VEGF-A and polyclonal antibodies used in ELISA (AF-293 and BAF-293), as well as the anti-VEGFR-2 goat polyclonal antibody AF357, were from R&D Systems (Abingdon, UK). Control rabbit and goat IgGs, were from Sigma-Aldrich. The Akt inhibitor SH-5 [D-3-deoxy-2-O-methyl-myo-inositol 1-[(R)-2-methoxy-3-(octadecyloxy) propyl hydrogen phosphate] was purchased from Enzo Life Sciences (Lausen, Switzerland).
Cell lines and stable transfection of VEGFR-2.
The origin and culture of M14 and GR-Mel cell lines have been previously described (12) . The isolation and transfection of M14C2 clone with the pcDNA3/VEGFR-2 plasmid (a generous gift of Dr K. Ballmer-Hofer, PSI, Zurich, Switzerland) or with the empty vector (pcDNA3) was performed according to previously described procedures (14) . Transfected cells expressing VEGFR-2 were identified by RT-PCR, utilising primers that amplify the fragment of the receptor cDNA sequence comprised between nucleotides 2012 and 2414, as previously described (12) .
M14-NV cells were transfected with a pRS plasmid containing a 29-mer shRNA sequence against NRP-1 (TI344368) or with a negative control shRNA pRS plasmid (TR20003), both of them from Origene (Rockville, MD). Transfections were performed as previously described (12) and cell subclones were selected in complete medium supplemented with 2.5 µg/ ml puromycin and analyzed for their NRP-1 content by Western blotting.
Real-time quantitative RT-PCR (qRT-PCR).
For each cell line analysed, 1 µg of total RNA was reverse-transcribed in 20-µl reaction volume containing Superscript II enzyme (Invitrogen, Paisley, UK) and the following primers: forward, 5'-GTC TAT GCC ATT CCT CCC CC-3'; reverse 5'-GAG ACA GCT TGG CTG GGCT-3'. qRT-PCR was then performed by the duallabelled fluorigenic probe method, using an ABI PRISM 7000 sequence detector (Perkin-Elmer, Groningen, The Netherlands), as previously described (14) . Expression levels of VEGFR-2 mRNA were calculated by the relative standard curve method. The level of VEGFR-2 transcript was then normalized to that of 18S RNA and referred to the values of the VEGFR-2-negative M14 cell line, to which the arbitrary value of 1.0 was assigned.
Western blot analysis. NRP-1 expression in the different melanoma cell lines was evaluated in cell extracts by western blot analysis, following a method already described (13) . The anti-NRP-1 mouse monoclonal antibody (mAb) A-12 and the anti-β-tubulin rabbit polyclonal antibody H-235 (used as a loading control) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and utilized at the final concentration of 0.2 µg/ml.
Evaluation of VEGF-A secretion.
Semi-confluent melanoma cell cultures were incubated in 0.1% BSA/RPMI-1640 medium without FBS for 24 h. Culture supernatants were then collected and concentrated at least ten-fold in Centriplus concentrators (Amicon, Beverly, MA). Cells were detached from the flasks with a solution of 1 mM EDTA in PBS (EDTA/PBS) and the total cell number/culture was recorded. Quantification of the amount of VEGF-A in the concentrated supernatants was performed using Maxisorp Nunc immunoplates (Nunc, Roskilde, Denmark) coated with goat anti-VEGF-A IgGs, as previously described (12) .
Migration and invasion assays. In vitro migration assays were performed using Boyden chambers equipped with 8-µm pore diameter polycarbonate filters (Nuclepore, Whatman Inc., Clifton, NJ), coated with 5 µg/ml gelatin (13) . Briefly, melanoma cells were collected from continuous cultures, washed, suspended in migration medium (1 µg/ml heparin/0.1% BSA in RPMI-1640) and loaded (2x10 5 cells) into the upper compartment of the Boyden chambers. Migration medium or migration medium containing 20 ng/ml VEGF-A was added to the lower compartment and the chambers incubated at 37˚C in a CO 2 atmosphere for 18 h (unless otherwise indicated). The filters were then removed from the chambers, cells fixed in ethanol, stained in crystal violet and those migrated, attached to the lower surface of the filters, counted under the microscope. Twelve high-magnification microscopic fields (magnification x200), randomly selected on triplicate filters, were scored for each experimental condition.
In vitro ECM invasion by melanoma cells was analysed in Boyden chambers as described for the migration assay, but utilising polycarbonate filters coated with 20 µg of the commercial basement membrane matrix Matrigel (BD Biosciences, Buccinasco, Italy) instead of gelatin (15) and allowing the cells to invade for 4 h, unless otherwise indicated.
In a set of experiments, migration or invasion assays were performed in the presence of antibodies against NRP-1, VEGFR-2 or matrix metalloproteinase-2 (MMP-2) or the corresponding control immunoglobulins (Igs). Melanoma cells were pre-incubated with the antibody under investigation for 30 min at room temperature in a rotating wheel. The cells were then loaded in the Boyden chambers without removing the antibody.
Evaluation of MMP-2 secretion. Melanoma cells were seeded into 6-well plates (2x10 5 cells/well) and allowed to grow near to confluence in complete medium. The cells were then cultured in 2 ml of 0.1% BSA/RPMI-1640 medium without FBS for 24 h. Afterwards, culture supernatants were collected, centrifuged at 600 x g for 10 min to remove cells in suspension and frozen at -20˚C till use. Cells were detached with EDTA/PBS and counted to determine the total number of cells in the culture. The amount of active MMP-2 present in the supernatant of the different cell cultures was determined using a human MMP-2 Quantikine immunoassay kit (R&D Systems).
Phosphorylation profiles of kinases and kinase substrates.
A human phospho-kinase array kit (ARY003, from R&D System) was used to determine in melanoma cells the relative level of phosphorylation of 46 phospho-acceptor sites, identifying a total of 37 polypeptides, comprising kinases and kinase substrates. Cell extracts were prepared as indicated by the manufacturer and each part of the array was incubated with an aliquot corresponding to 500 µg of protein.
Positive signals were detected on X-ray film by a chemiluminescent reaction, as indicated in the manual of the kit. Relative levels of protein phosphorylation were determined by densitrometric quantification of the spots obtained for each phospho-acceptor site and normalization of the results with respect to the array internal positive controls.
Determination of phospho-Akt (T308) levels. Melanoma cells (2-4x10 4 ) were cultured in 96-well plates to near confluence and then fixed in 4% formaldehyde/PBS for 20 min at room temperature. Phosphorylation of Akt on T308 was determined using a human phospho-Akt (T308) cell-based ELISA (R&D Systems). This assay directly quantifies in the cells the amount of Akt phosphorylated on T308 with respect to the total amount of Akt protein.
Results
Characterization of M14C2 subclones. The human melanoma cell line M14 does not express either VEGFR-2 or VEGFR-1 and displays only low levels of NRP-1 (12) . A clone of this cell line (i.e., M14C2) was, therefore, utilized to investigate whether NRP-1 expression participates in the VEGF-A/VEGFR-2 autocrine loop that promotes melanoma cell invasiveness (13) . M14C2 cells were transfected with a plasmid containing the cDNA encoding VEGFR-2 or with the empty vector and subclones expressing this receptor and/ or NRP-1, or negative for both polypeptides, were identified. Based on the expression levels of NRP1 and VEGFR-2, four subclones were then selected: one subclone obtained from M14C2 cells transfected with the empty vector, namely M14-C, which does not express either VEGFR-2 or NRP-1; three subclones obtained from M14C2 cells transfected with the VEGFR-2 containing plasmid, namely M14-NV, which expresses both receptors, M14-N, which expresses only NRP-1 at levels comparable to those displayed by the M14-NV subclone and M14-V, which expresses only VEGFR-2 at levels comparable to those displayed by the M14-NV subclone ( Fig. 1A and B) .
Melanoma cells expressing either NRP-1 alone or VEGFR-2 alone displayed a 2-fold increase in the levels of VEGF-A secretion as compared with the cells negative for both receptors (Fig. 1C) . Moreover, the simultaneous expression of VEGFR-2 and NRP-1 was accompanied by a further enhancement of VEGF-A secretion by melanoma cells (Fig. 1C) .
The analysis of the ability of the four transfected subclones to spontaneously invade the ECM revealed that the cells expressing only NRP-1 were endowed with higher invasiveness as compared to the cells devoid of both NRP-1 and VEGFR-2 or expressing only the latter receptor (Fig. 1D) . Moreover, the cells co-expressing VEGFR-2 and NRP-1 showed an invasive capacity significantly higher than that displayed by the cells expressing only NRP-1 (Fig. 1D) .
The transfected subclones were also analyzed for the ability to migrate under basal conditions or in response to VEGF-A. Higher basal levels of migration were observed in NRP-1 expressing cells with respect to the cells negative for both NRP-1 and VEGFR-2 or expressing only the latter receptor (Table I) . As expected, only the subclones expressing VEGFR-2 displayed a chemotactic response to VEGF-A. 
Involvement of NRP-1 in melanoma cell migration and ECM invasion.
The involvement of NRP-1 expression in melanoma cell ability to migrate and invade the ECM was further investigated using an anti-NRP-1 antibody against the MAM (meprin, A5, μ-phosphatase) domain of this polypeptide, reported to be involved in the receptor oligomerization (16, 17) . Treatment with this antibody drastically reduced the migratory response of M14-NV cells to VEGF-A (Fig. 2A) . Comparable results were obtained using an anti-VEGFR-2 antibody that blocks VEGF-A binding to this receptor (Fig. 2A) . The anti-NRP-1 antibody also inhibited M14-NV and M14-N cell ability to spontaneously invade the ECM (a 55 and 33% inhibition, respectively) (Fig. 2B) . As expected, the anti-VEGFR-2 blocking antibody downmodulated M14-NV cell invasiveness (~41% inhibition) (Fig. 2B) .
Downmodulation of NRP-1 expression in M14-NV cells was achieved by transfection of these cells with a pRS plasmid containing a specific 29-mer shRNA sequence (M14-NV/ (Fig. 2C) . M14-NV/NAS cells showed a 46% decrease in the ability to invade the ECM (Fig. 2D) . Moreover, their ability to migrate either in response to VEGF-A or in non-stimulating conditions was abrogated or halved, respectively (Fig. 2E) .
MMP-2 secretion by M14C2 subclones.
In an attempt to shed light on the mechanism by which NRP-1 promotes melanoma cell invasiveness, secretion of the metalloproteinase MMP-2 by the different transfected subclones was analyzed. M14-NV and M14-N cells showed levels of MMP-2 secretion ~6-fold higher than those displayed by M14-V or M14-C cells (Fig. 3A) , strongly suggesting that NRP-1 expression up-modulates the secretion of this metalloproteinase by human melanoma cells. Moreover, in vitro ECM invasion by M14-NV and M14-N cells was inhibited in the presence of an anti-MMP-2 antibody, confirming the involvement of this metalloproteinase in the elevated invasiveness of NRP-1 expressing cells (Fig. 3B) .
Involvement of Akt signalling pathway in the invasiveness of NRP-1 expressing melanoma cells.
The results obtained in the functional assays described above, suggested that NRP-1 might activate in melanoma cells signal transduction pathways independently of its interaction with VEGFR-2. With the intent to identify any of these signal transduction pathways, the constitutive phosphorylation status of a set of kinases and kinase substrates was determined in NRP-1 expressing cells with respect to NRP-1 negative cells, using a human phosphokinase array kit.
The results indicated that the phosphorylation status of several proteins was different between NRP-1-positive and NRP-1-negative cells (Table II) . The phospho-acceptor sites that showed an increased phosphorylation level of ≥2-fold in M14-NV and M14-N cells with respect to M14-C and M14-V cells, are shown in Fig. 4A . The highest increase in the level of phosphorylation was observed on T308 of Akt [phosphoAkt (T308)] and S63 of c-Jun. A remarkable increase in the level of phosphorylation was also detected on S15 of p53, T421/S426 and T229 of the ribosomal S6 kinases p70S6K, S380 and S221 of the ribosomal S6 kinases RSK and Y693 of STAT4 (Fig. 4A) .
On the other hand, only four kinases displayed a significant reduction of phosphorylation levels in NRP-1 expressing cells, namely the mammalian target of rapamycin (mTOR) and three members of the Scr family of non-receptor tyrosine kinases (Src, Fyn and Hck) (Fig. 4B) .
Aberrant activation of the PI3K/Akt signalling pathway has been implicated in melanoma onset, progression and chemoresistance (18, 19) . Thus, studies were performed to investigate the possible role of increased Akt phosphorylation in M14-NV and M14-N cell invasiveness. To this end, the levels of phospho-Akt (T308) in the four transfected subclones were determined by a cell-based ELISA method, which confirmed the results obtained with the phosphokinase Migration assays were performed in Boyden chambers equipped with gelatin coated polycarbonate filters, in the absence or in the presence of VEGF-A (20 ng/ml in migration medium) as stimulus.
Values represent the number of migrated cells per microscopic field (magnification x200) and are the mean of at least three independent determinations ± SD. b The migration index was calculated as the ratio between the number of cells/microscopic field in the experimental condition analysed and the number of cells/microscopic field in the basal condition (i.e., in the absence of any stimulus). The migration index in the basal condition corresponds to 1. Table II . Phosphorylation levels of a set of kinases and kinase substrates in the different transfected M14C2 subclones. The phosphorylation level of the indicated proteins was simultaneously analyzed in cell extracts from the different transfected subclones using a human phospho-kinase array kit, as described in Materials and methods. Relative levels of protein phosphorylation were determined by densitometric quantification of the spots obtained and normalization of the results with respect to the internal positive controls. Data refer to a representative experiment performed with duplicate samples.
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array (Fig. 5A) . Actually, untreated M14-NV and M14-N cells expressed higher levels of phospho-Akt (T308) as compared with the NRP-1-negative cells. Using the same immunoassay, the effects of a specific Akt inhibitor (SH-5), which prevents phosphatidylinositol-trisphosphate binding to this kinase (20) , were also investigated in M14-NV and M14-N cells. As expected, melanoma cell exposure to SH-5 caused a significant reduction in the levels of phosphorylated Akt (Fig. 5A) . Moreover, pre-treatment of M14-NV and M14-N cells with SH-5 also resulted in a marked downmodulation of cell invasive capacity (Fig. 5B) , strongly suggesting that the activation of Akt contributes to the higher invasiveness of melanoma cells expressing NRP-1.
Discussion
NRP-1, when co-expressed with VEGFR-2, is considered a VEGF-A binding co-receptor, amplifying not only endothelial cell but also tumour cell response to VEGF-A. The results of the present study demonstrate that NRP-1 plays an important role in the regulation of melanoma cell ability to migrate and invade the ECM when expressed in cells also positive for VEGFR-2. Indeed, spontaneous in vitro ECM invasion by M14-NV cells expressing both NRP-1 and VEGFR-2, was significantly higher than that of M14-V cells expressing solely VEGFR-2 and was downmodulated not only by antibodies specific for VEGFR-2 but also by anti-NRP-1 antibodies and NRP-1 knockdown. Non-stimulated and VEGF-A-stimulated M14-NV cells also showed a higher level of in vitro migration as compared with M14-V cells, either non-stimulated or exposed to VEGF-A. Notably, the chemotactic response to VEGF-A of M14-NV cells was almost abrogated not only by antibodies specific for VEGFR-2 but also by anti-NRP-1 antibodies and NRP-1 knockdown. This finding demonstrates that NRP-1, acting as a co-receptor for VEGF-A, co-operates with VEGFR-2 to promote melanoma cell migration in response to this cytokine, as previously described in other tumour types (5,7). Moreover, melanoma cells expressing both VEGFR-2 and NRP-1 produce VEGF-A amounts significantly higher than those secreted by the cells expressing only VEGFR-2. This feature might enhance tumour angiogenesis and sustain the VEGF-A/VEGFR-2 autocrine loop in vivo, leading to increased tumour growth and metastases. Considerable experimental evidence has suggested that the intracellular domain of NRP-1 possesses the ability to activate signal transduction pathways also independently of VEGFR-2 tyrosine kinase activity (21, 22) . Actually, the three C-terminal residues of NRP-1 allow the interaction of this polypeptide with protein adapters that contain the PDZ (PSD-95/Dlg/ ZO-1) domain that could connect NRP-1 with intracellular signalling molecules (23) . An example of such kind of proteins is synectin, an important modulator of arterial development and branching through its involvement in the regulation of cell polarization and migration (24) .
Consistent with the ability of NRP-1 to activate signal transduction pathways independent of VEGFR-2, the results of our study show that the expression of NRP-1 is also able to promote cell migration and ECM invasion in the absence of VEGFR-2 co-expression. Indeed, M14-N cells displayed elevated levels of spontaneous in vitro migration and ECM invasion as compared not only with M14-C cells, negative for both NRP-1 and VEGFR-2, but also with M14-V cells. Both biological processes are activated during tumour metastatic spreading and depend on the degradation and remodelling of the ECM and basement membranes by proteolytic enzymes. In particular, MMP-2 expression has been correlated with melanoma progression and it represents an unfavourable prognostic factor for this type of cancer (25, 26) . Our results demonstrate that the NRP-1 expression is by itself sufficient to upregulate active MMP-2 secretion and that the activity of this enzyme is essential for ECM invasion by melanoma cells, as described for other tumour types (27) .
In an attempt to identify signal transduction pathways activated by NRP-1 which might promote melanoma cell invasiveness, the phosphorylation status of a set of 37 different polypeptides (comprising kinases and kinase substrates) was comparatively analyzed in NRP-1-positive and NPR-1-negative cells. A marked increase in the phosphorylation of the transcription factor c-Jun at the S63 site and of the serine/threonine kinase Akt, at the T308 site was observed in NRP-1 expressing cells. c-Jun is known to be implicated in the activation of MMP expression (28) . On the other hand, Akt activation has been shown to induce ECM invasion and MMP-2 secretion in epithelial cells (29) and phospho-Akt expression in melanoma specimens has been found to increase with disease progression and to inversely correlate with patient survival (18) . Thus, simultaneous activation of Akt and c-Jun in melanoma cells expressing NRP-1 might co-operate to induce MMP-2 secretion and promote ECM invasion. This hypothesis is supported by the observation that inhibition of Akt activity resulted in a remarkable decrease of ECM invasion by melanoma cells expressing solely the NRP-1.
The increased levels of phospho-Akt (T308) in NRP-1 expressing cells might be the result of the reduced phosphorylation of mTOR observed in these cells. The mTOR protein kinase exists in two complexes, mTORC1 and mTORC2, depending on the proteins to which it associates. mTORC1, which is activated downstream of Akt in the PI3K/Akt pathway, phosphorylates two major substrates, namely p70S6K and 4E-BP1. Phosphorylation of p70S6K on T389 causes a feedback inhibition of the receptor tyrosine kinases responsible for Akt phosphorylation (30) . Moreover, mTORC1 phosphorylates and activates also the protein phosphatase 2 (PP2A), which dephosphorylates p53 at Ser15 (31) and Akt at T308 (32) . mTORC2 complex has been shown to directly phosphorylate Akt and SGK1. In particular, phosphorylation of Akt on S473 by mTORC2 enhances the catalytic activity of Akt already phosphorylated on T308 by the serine/threonine kinase PDK1 (phosphoinositide-dependent kinase 1). In this context, mTOR kinase activity downmodulation and low levels of p70S6K phosphorylation on T389 result in the relieve of receptor tyrosine kinases feedback inhibition by mTORC1 complex, leading to an increase of Akt phosphorylation even if mTORC2 activity is reduced (33, 34) . Interestingly, it has been demonstrated that mTORC1 activity down-modulation results in Akt phosphorylation on T308, but not on S473 and that phospho-Akt (T308) is active and able to phosphorylate key substrates of the PI3K/Akt signal transduction pathway (35) . These data might explain why upregulation of phosphoAkt (T308) in melanoma cells expressing NRP-1 results in the promotion of cell invasiveness in the absence of a parallel upregulation of Akt phosphorylation on S473.
Our study demonstrates that in melanoma cells expressing NRP-1 mTOR phosphorylation is reduced with respect to NRP-1 negative cells and that phosphorylation of p70S6K on T389 in these cells is also low, as compared to p70S6K phosphorylation on T421/S424 or T229. Moreover, consistent with the literature findings, NRP-1 expressing cells display increased levels not only of phospho-Akt (T308), but also of phospho-p53 (S15). Therefore, our results suggest that the expression of NRP-1 in melanoma cells might favour the up-modulation of a signal transduction pathway that involves phospho-Akt (T308) and might result in the promotion of migratory and invasive capabilities in these cells.
In addition, phosphorylation of two ribosomal S6 kinases was found to be down-modulated in NRP-1 expressing cells, namely p70S6K and RSK. p70S6K, besides having the abovementioned role in the negative feedback induced by mTOR, when phosphorylated by different kinases on other sites, such as the T229, might act as a positive regulator of melanoma cell invasiveness (36) . RSK is activated through the ERK pathway (37) and has been shown to be an important common effector for multiple migratory stimuli (38) (39) (40) . Both RSK and p70S6K contain PDZ regions (36, 37) which might interact with the carboxi-terminus end of NRP-1, in a way similar to that already described for synectin (24) . NRP-1 might therefore recruit S6 kinases to the membrane and favour their activation by PDK1 that, besides phosphorylating Akt, is also able to activate p70S6K and RSK (41) . NRP-1 might, in this way, positively modulate both Akt and ERK signalling pathways.
Cutaneous malignant melanoma is endowed with high invasiveness and metastatic potential as well as with elevated chemo-and radioresistance. During melanoma progression, the transition from the radial growth phase (RGP) to the vertical growth phase (VGP) is a key event, given that RGP melanomas are mostly curable by surgical resection, whereas VGP melanomas have the ability to metastasize (2, 5) . This transition seems to be associated with an increase of VEGF-A expression by the tumour cells (3) . In this context, the results herein presented demonstrate that NRP-1 plays a critical role in melanoma cell migration sustained by the VEGF-A/ VEGFR-2 autocrine loop. Moreover, they provide for the first time evidence that NRP-1 expression strongly promotes melanoma cell invasiveness also in the absence of VEGFR-2 and that this effect depends, at least in part, on Akt activation and on enhanced secretion of MMP-2. A better understanding of the mechanisms by which NRP-1 regulates melanoma invasive capacity might help to design novel and more effective strategies, including the development of NRP-1 antagonists, for the treatment of the metastatic disease, that presently has few therapeutic options.
